Group items tagged

The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.

As the new school year approaches parents won't just be in a flurry of buying new pencil cases and the next size up in shoes but also will be looking to stock their cupboard for their health needs for the next year. Along with the Supermarket's Back-to-School sales there is also the opportunity to help parents with a clever display of the top needed cupboard accessories with some smart recommendations to help with choices. Looking at the UK retail market it is also worth considering that we are seeing a push for sustainability in products with those touting green credentials starting to stand out from the competitors but with a backdrop of rising prices making price perhaps more important than ever. Cuts and scrapes One to definitely think about in the children's health range for back to school is plasters and wound cleaning preparations for those inevitable playground grazed knees, cuts and scrapes. With a focus on sustainability and some strong green credentials Elastoplast Green and Protect should be considered for any back to school health display with eco-friendly construction and a climate neutral product but there is also Patch Kids Bamboo Sensitive Plasters which boast being home compostable.

Pharmacy bodies are "bitterly disappointed" that the latest deal on the national contract makes no commitment to "fresh funding", with one organisation calling it "the biggest dis-service ever done" to community pharmacy. The only commitment made in monetary terms was one in which NHS England agreed to write off a sum of £100m in excess margin earned by contractors in previous years. This allowance, which can't be seen as new cash injection, was said to have been made in recognition of the pressures facing the sector. The figure - reached after what the the Pharmaceutical Services Negotiating Committee called "a tense period of negotiations" with the Department of Health and Social Care and NHS England - will cover the final two years of the current five-year Community Pharmacy Contractual Framework. The deal was announced by PSNC chief executive Janet Morrison at an annual LPC Conference in Manchester on Thursday (22 September). Welcoming the attendees, she assured everyone that the committee was well aware of the pressures the sector was facing. "I heard how contractors are feeling and their frustrations over growing pressure and lack of financial support from the government. They confirmed that many now are unable to deliver the full range of services, and others are struggling to maintain core levels of services. And the ongoing impact of capacity and workforce crisis is critical, leading to temporary closures.

The Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI) have reached an agreement on the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The landmark deal will save the NHS £14 billion over 5 years in medicines costs, boost the nation's health, and support research investment. The new VPAG scheme, which will be a non-contractual voluntary agreement between DHSC and ABPI, will run for 5 years from 1 January 2024 until 31 December 2028. It will double the annual allowed growth of sales of branded medicines from two per cent per year in 2024 to four per cent per year by 2027.

New GSK raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a standalone prescription medicine and vaccine business since carving out its consumer health division Haleon. After years of underperformance relative to its peers and missing out on the lucrative market for the first set of COVID-19 vaccines, GSK has delivered a string of strong results. The latest is led by a record quarter for its blockbuster shingles vaccine Shingrix and higher-than-expected revenue from its COVID therapy, Xevudy. Having survived a revolt by activist investors Elliott and Bluebell last year, GSK's prospects have been boosted by clinical trial success, though concerns remain around U.S. litigation over heartburn drug Zantac. Thousands of lawsuits have been filed in the United States against a raft of drugmakers over allegations the heartburn drug contains a probable carcinogen.

The voter turnout for the Royal Pharmaceutical Society (RPS) England this year has dropped to 7.3 per cent. Out of a total 18,333 eligible voter only 1,336 voter elected Danny Bartlett to the vacancy on the English Pharmacy Board. This year, four nominations were received for one substantive place on the English Pharmacy Board. One nomination was received for a single vacancy on the Welsh Pharmacy Board. Richard Evans has been elected unopposed to the vacancy on the Welsh Pharmacy Board. There were no vacancies this year on the Scottish Pharmacy Board. Therefore, no election was required for the Welsh Pharmacy Board nor the Scottish Pharmacy Board. Sarwat (Sorbi) Khattak has been elected for a period of one year to fill the casual vacancy.

The National Pharmacy Association (NPA) survey revealed that 93 per cent of respondents experienced 'at least one month' of negative cash flow across their pharmacy business in 2022. Nine out of 10 pharmacy owners responding to NPA survey said they made a net loss dispensing medicines for the NHS during 2022, for at least one month of the year. According to the poll, 48 per cent of them lost money on this core NHS service for six months or more. 45 per cent said their overall outgoings had exceeded overall income in at least six months of the year. NPA Chair Andrew Lane said: "This survey shows the bleak financial reality facing many independent pharmacies after years of underfunding. Dispensing at a loss and negative cashflow is clearly unsustainable." "This funding crisis must be addressed urgently or pharmacies will fall into a spiral of declining services and ultimately widespread closures, he added. "Tragically, the story is playing out very much in line with independent research commissioned by the NPA last year, which warned of a nationwide financial emergency in our sector."

A new report, published by the Office of National Statistics (ONS), has revealed worrying statistics about the mental health of children and young people in England. The report is based on NHS survey on Mental Health of Children and Young People in England 2023, which showed that one in five children and young individuals aged eight to 25 were grappling with probable mental disorders. The report highlighted that 20.3 per cent of eight to 16-year-olds showed signs of mental distress in 2023. Among 17 to 19-year-olds, the proportion rose to 23.3 per cent, while in 20 to 25-year-olds, it stood at 21.7 per cent. The rates of probable mental disorders were similar for boys and girls, while for 17- to 25-year-olds, rates were twice as high for young women than young men.

In the next 10 years, the incidence of first-time stroke cases in the UK is projected to increase by 60 per cent, costing the government £75bn in healthcare and lost productivity, a charity has suggested. A new manifesto published by the Stroke Association has urged the next UK government to make stroke "the priority", stressing that the next decade is crucial for stroke prevention, treatment and recovery. Currently, stroke is the UK's fourth biggest killer and a leading cause of disability. On a daily basis, 281 individuals experience a stroke. Next year, the cost of stroke in the UK will be £43 billion. The charity predicted that by 2035, there will be 151,000 hospital admissions due to stroke every year, averaging 414 admissions per day, with 42,000 people estimated to die every year. In 2035, the UK is projected to have 2.1 million stroke survivors, imposing a financial burden of £75 billion on the public purse, nearly half the current NHS budget.

The National Institute for Health and Care Excellence (NICE) has recommended first new treatment - 'romosozumab' for osteoporosis for over a decade. Thousands of people in England and Wales with severe osteoporosis who are at high risk of fracture are set to benefit from a new treatment - romosozumab - after NICE published the final draft guidance. Over 20,000 people could be eligible for the treatment according to the company. Clinical trial evidence showed that romosozumab (also known as EVENITY and made by UCB) followed by alendronic acid is more effective at reducing the risk of fractures than alendronic acid alone. Osteoporosis is a disease that causes bones to become thin and fragile. Many people with osteoporosis show no symptoms, but they may be at increased risk of fracture. Osteoporosis leads to nearly 9 million fractures around the world each year, and over 300,000 people per year attend hospitals in the UK with fractures caused by osteoporosis.

Superdrug is bolstering its physical presence by launching 25 new stores this year as it celebrates its 60th year on the British high street. Additionally, the health and beauty retailer has announced plans to extend seven of its existing branches and refit another 60 throughout 2024. However, the retailer has confirmed the locations for only four upcoming stores - Wheatley Centre Shopping Parkin Doncaster, St David's Centre in Cardiff, Bluewater Shopping Centre and Westfield Stratford City. As reported by Mirror, the Donacaster site is expected to open by the end of this month, followed by the relocation of its existing Cardiff store to a new 11,3000 sq. ft space shortly thereafter. Superdrug is also shifting its Westfield Stratford City store, doubling its size to 9,892 sq. ft. Likely to be opened in the summer, it will be one of the retailer's biggest stores.

So long to 2020! In the wake of a new year, here are 3 reflections that helped us here at HospitalRecruiting survive the last. Happy (almost) New Year! full article: https://www.hospitalrecruiting.com/blog/7052/3-ideas-that-saved-me-from-2020 #newyear #inspiration #meditation #stoic

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.

The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair. DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly. With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca. She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services. In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to prepare for the proposed spin out of the company from its parent, Novartis, expected later this year. She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing the sustainability of our industry so we can continue to play our vital part in the health of the nation." Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through her role on the BGMA board and leadership of a key strategic committee.

he British Generic Manufacturers Association (BGMA) has voted Pete Kelly, managing director of Accord UK, to become its new chair. He replaces Peter Ballard, who has completed his second tenure as the association's chair and will now serve a further year as vice-chair. Pete leads the UK operations of Accord, one of the largest generic and biosimilar manufacturers in Europe. In the UK, the company currently supplies a fifth of all generic medicines. Mark Samuels, chief executive of BGMA, said: "We are very fortunate to have someone of Pete's experience and leadership qualities to take on the mantle of chair of the association. The industry faces a challenging period on many fronts, and Pete's input will be invaluable. "I would also like to record my enormous gratitude to Peter Ballard, our out-going Chair who has been an incredible servant to the association over many, many years. He will continue for another year as vice-chair, and we are pleased to have his continuing advice."

The UK government on Thursday (8 May) launched a new plan to tackle antimicrobial resistance (AMR), a global issue that makes infections difficult or impossible to treat. This is the second phase of a series of 5-year national action plans, aimed at supporting the government's 20-year vision to contain and control AMR by 2040. With the launch of this new national action plan, the UK commits to reducing its use of antimicrobials - such as antibiotics, antifungals and antivirals - in humans and animals. Additionally, it aims to strengthen surveillance of drug-resistant infections before they emerge and incentivise industry to develop the next generation of treatments. There are also plans to expand initiatives such as the world-first 'subscription model' for antimicrobials, launched in 2019 as a pilot.

Over a century-year-old Boots pharmacy in St James's Street, Brighton shut its doors permanently on Saturday (20 January) leaving the communities disappointed. The branch in Kemp Town, which was opened to the public for the first time in 1914, was supposed to close on November 19 last year but continued trading into the new year, The Argus reported. Locals are not happy with the retailer's decision to close the store as some say it used to be "always busy with prescriptions and people buying things." Another person recalled that Boots had earlier closed two pharmacies, one on Lewes Road, Brighton, and another on Church Road, Hove. The American-owned health and wellbeing chain is in the process of closing more UK branches in the coming months as it's targeting to reduce its store portfolio to 1,900 from 2,200.

Nasofed Anti Viral Nasal Spray, from EM Pharma, is delighted to welcome Dr Sarah Jarvis as medical adviser for its winter colds and flu consumer awareness campaign. Sarah is well known as a trusted and reliable source of medical advice through her various media roles as Resident GP on BBC R2's The Jeremey Vine Show, Good Morning Britain, Channel 5 and ITV News. Says Paul Walsh, EM Pharma Managing Director: "Dr Sarah will be offering advice on how people can best protect themselves and their families against seasonal and year-round viruses, including the use of Nasofed anti viral thixotropic nasal spray as an extra layer of protection particularly in situations of increased viral risk." Dr Sarah adds: "Viruses continue to affect our daily lives, whether that be year-round viruses or more seasonal viruses such as colds and flu and RSV, all of which are expected to be particularly prevalent this year. In situations of increased viral risk, a thixotropic nasal spray delivering anti viral ingredients will help protect you. It's a real step forward in virus prevention, not just for colds and flu, but also year-round viruses."

As part of a new blueprint for primary care, the government today (May 9) announced an investment of £645 million over two years to expand community pharmacy services in England. In a statement, NHS England said: "For the first time ever, patients who need prescription medication will be able to get it directly from a pharmacy, without a GP appointment, for seven common conditions including earache, sore throat, or urinary tract infections." Prime minister Rishi Sunak hopes that the measures will help end the "all-too stressful wait on the end of the phone for patients" by freeing up 15 million slots at doctors' surgeries over the next two years. "We will end the 8am rush and expand the services offered by pharmacies, meaning patients can get their medication quickly and easily," he said Almost half a million women will no longer need to speak to a practice nurse or GP to access oral contraception and will instead be able to pop into their local pharmacy for it, according to the government announcement. Blood checks for people suffering from moderate risk of heart attack or stroke conducted in community pharmacies will more than double from 900,000 last year to 2.5 million next year. NHS chief executive Amanda Pritchard said the "ambitious package" would help transform how care is provided within the health service "with pharmacies playing a central role in managing the nation's health including providing lifesaving checks and medication for common conditions for the first time.

A 14-year-old heart transplant campaigner visited Phoenix UK's headquarters in Runcorn recently to raise awareness of the importance of organ donations. The visit by Max Johnson, founder of 'Max and Keira's law', along with his mother Emma, coincided with the launch of Phoenix UK's partnership with the British Heart Foundation (BHF) in which the pharmaceutical provider committed to set a donation goal of raising £20,000 by June 2023 for the heart charity. Max and Emma met with Phoenix UK's employees and gave a talk on the importance of the work they have carried out on behalf of BHF. Max, who was diagnosed with dilated cardiomyopathy when he was eight years old, also shared his own story. His life was saved when he was gifted with Kiera Ball's heart - a nine-year-old girl from Devon who died in a car accident. Max and his family campaigned tirelessly to change the law in England in favour of an opt-out system for organ donation since he was 'gifted' his new heart. 'Max and Keira's Law' passed in May 2020.